Company Overview of Protein Sciences Corporation
Protein Sciences Corporation develops and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers Flublok, an influenza vaccine; Panblok, a vaccine for pandemic influenza; FluNhance that is used as an additive to influenza vaccines; and SARS (D3252), a Severe Acute Respiratory Syndrome vaccine, which is used as an antigen for severe acute respiratory syndrome virus. It also provides baculovirus expression vector system for prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applications; GeneXpress, which provides protein production services; expresSF+ cells that optimizes protein production; and research ant...
1000 Research Parkway
Meriden, CT 06450
Founded in 1983
Key Executives for Protein Sciences Corporation
Head of Government and Clinical Affairs
Executive Chairman and Global Head of Business Development
Compensation as of Fiscal Year 2014.
Protein Sciences Corporation Key Developments
Protein Sciences Corporation Signs License Agreement with Laboratorios Liomont
Aug 13 14
Protein Sciences Corporation and Laboratorios Liomont S.A. de C.V. (Liomont) have signed a licensing agreement that grants Liomont an license to Flublok (R) (seasonal) and Panblok(R) (pandemic) influenza vaccines for Mexico market and other Latin American countries. Under the terms of the agreement, Liomont will seek regulatory approval for Flublok in Mexico and initially sell Flublok manufactured by Protein Sciences. Liomont has also obtained rights to manufacture Flublok and Panblok in Mexico. Protein Sciences is entitled to significant license and milestone payments and royalties on sales.
Protein Sciences Corporation Receives Approval from FDA for 2014/15 Formulation of Flublok(R) Influenza Vaccine
Jul 8 14
Protein Sciences Corporation announced that the FDA has approved the company's strain change amendment for its seasonal influenza vaccine, Flublok. Every year influenza vaccine manufacturers must receive approval from the Agency for changes they make to the upcoming season's manufacturing process and product formulation, as the influenza vaccine is adapted annually. Early approval for Flublok will enable delivery on time to healthcare providers in the fall. This is especially important for those that rely on Flublok's unique properties for protection from the flu; namely, that the vaccine is egg-free, highly pure and triple the strength compared to conventional influenza vaccines.
Protein Sciences Corporation Announces Earlier Availability and Broader Distribution Coverage of its Modern, Egg-Free Flublok Influenza Vaccine for 2014/2015
Jun 10 14
Protein Sciences Corporation announced it will have more doses, earlier availability and broader distribution coverage of its modern, egg-free Flublok(R) Influenza Vaccine for the 2014/2015 season. Up to 500,000 doses of the vaccine will be manufactured, and the first doses will be available in September. ASD Specialty Healthcare and its Besse Medical and Oncology Supply divisions have been added as a distributor of Flublok. FFF Enterprises will continue to be a distributor.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 25, 2013
Most Searched Private Companies
Sponsored Financial Commentaries